Journal articles
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre
1
Caroline Denis
1
Caroline Soulas
1
Clarisse Bourbon-Caillet
1
Julie Lopez
1
Thomas Arnoux
1
Mathieu Blery
1
Cécile Bonnafous
1
Laurent Gauthier
1
Ariane Morel
1
Benjamin Rossi
1
Romain Remark
1
Violette Breso
1
Elodie Bonnet
1
Guillaume Habif
1
Sophie Guia
2
Ana Inés Lalanne
3
Caroline Hoffmann
3
Olivier Lantz
3
Jérome Fayette
4
Agnès Boyer-Chammard
1
Robert Zerbib
1
Pierre Dodion
1
Hormas Ghadially
5
Maria Jure-Kunkel
6
Yannis Morel
1
Ronald Herbst
7
Emilie Narni-Mancinelli
2
Roger Cohen
8
Eric Vivier
2, 1, 9
Pascale Andre 1
Author
Caroline Denis 1
Author
Caroline Soulas 1
Author
Clarisse Bourbon-Caillet 1
Author
Agnès Boyer-Chammard 1
Author
Robert Zerbib 1
Author
Pierre Dodion 1
Author
Hormas Ghadially 5
Author
Maria Jure-Kunkel 6
Author
Yannis Morel 1
Author
Ronald Herbst 7
Author
Emilie Narni-Mancinelli 2
Author
Roger Cohen 8
Author
Eric Vivier 2, 1, 9
Author IdHAL : eric-vivier ResearcherId : http://www.researcherid.com/rid/F-8939-2010
1
Innate Pharma (117, Avenue de Luminy - BP 30191 13276 Marseille Cedex 09 - France)
2
CIML - Centre d'Immunologie de Marseille - Luminy (Parc scientifique et technologique de Luminy - 163, avenue de Luminy - Case 906 - 13288 Marseille cedex 09 - France)
- AMU - Aix Marseille Université : UM 2 (Aix-Marseille Université Jardins du Pharo 58 Boulevard Charles Livon 13284 Marseille cedex 7 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR_S 1104 (101, rue de Tolbiac, 75013 Paris - France)
- CNRS - Centre National de la Recherche Scientifique : UMR7280 (France)
3
U932 - Immunité et cancer (INSTITUT CURIE - SECTION DE RECHERCHE
26 RUE D'ULM
75248 PARIS - France)
- UPD5 - Université Paris Descartes - Paris 5 : UMR_S 932 (12, rue de l'École de Médecine - 75270 Paris cedex 06 - France)
- Institut Curie [Paris] ( 26 rue d'Ulm - 75248 Paris - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U932 (101, rue de Tolbiac, 75013 Paris - France)
4
Centre Léon Bérard [Lyon] (28, rue Laennec 69373 LYON Cedex 08 - France)
5
MedImmune Ltd [Cambridge, UK] (Milstein Building
Granta Park
Cambridge CB21 6GH - United Kingdom)
- Granta Park [Cambridge, UK] (United Kingdom)
6
MedImmune Cambridge (Sir Aaron Klug Building, Granta Park, Great Abington, Cambridgeshire, CB21 6GH - United Kingdom)
- CAM - University of Cambridge [UK] (The Old Schools, Trinity Lane, Cambridge CB2 1TN - United Kingdom)
- MedImmune Ltd (France)
7
MedImmune Ltd - MedImmune Ltd (Milstein Building
Granta Park
Cambridge CB21 6GH - United Kingdom)
8
Abramson Cancer Center (Philadelphia, PA - United States)
- Perelman School of Medicine (Philadelphia - United States)
- University of Pennsylvania [Philadelphia] (3451 Walnut Street, Philadelphia, PA 19104 | 215-898-5000 - United States)
9
TIMONE - Hôpital de la Timone [CHU - APHM] (France)
Abstract : Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8+ T cell effector functions in mice and humans. Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various tumor cells and rescued CD8+ T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective response rate. Most common adverse events were fatigue (17%), pyrexia (13%), and headache (10%). NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may complement first-generation immunotherapies against cancer.
Document type :
Journal articles
Domain :
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-02023782
Contributor : Carine Dou Goarin Connect in order to contact the contributor
Submitted on : Monday, February 18, 2019 - 4:36:35 PM
Last modification on : Thursday, October 21, 2021 - 4:01:53 AM
Contributor : Carine Dou Goarin Connect in order to contact the contributor
Submitted on : Monday, February 18, 2019 - 4:36:35 PM
Last modification on : Thursday, October 21, 2021 - 4:01:53 AM
Licence
Distributed under a Creative Commons Attribution 4.0 International License
Links full text
Identifiers
- HAL Id : hal-02023782, version 1
- DOI : 10.1016/j.cell.2018.10.014
- PUBMEDCENTRAL : PMC6292840
Collections
UNIV-AMU | CNRS | CERCLE | CURIE | FNCLCC | UNIV-PARIS5 | USPC | UNIV-PARIS | PSL
Citation
Pascale Andre, Caroline Denis, Caroline Soulas, Clarisse Bourbon-Caillet, Julie Lopez, et al.. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell, Elsevier, 2018, 175 (7), pp.1731-1743.e13. ⟨10.1016/j.cell.2018.10.014⟩. ⟨hal-02023782⟩
Metrics
Record views